Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy.

J Thorac Oncol 2013 May;8(5):582-6

Department of General, Visceral and Tumor Surgery, University of Cologne, Germany.

Introduction: On the basis of the results of recent clinical trials, histology-based decision-making for therapy of non-small-cell lung cancer has been advocated. We hypothesized associations of the biomarkers excision repair cross-complementing 1 (ERCC1), ribonucleotide reductase M1 (RRM1), and thymidylate synthase (TS) with histology as a contributing factor to reported differences in chemotherapy outcomes between squamous cell carcinoma (SCCA) and adenocarcinoma (AC) subtypes. Here, we report analysis of the Response Genetics Inc., database and implications for histology-based therapy.

Methods: RNA from microdissected formalin-fixed paraffin-embedded tumors was extracted and analyzed as previously described. Specimens from 2540 individual non-small-cell lung cancer patients were analyzed for one or more biomarkers, of which 1457 were categorized as AC or SCCA.

Results: For each biomarker, gene expression was lower in AC compared with SCCA (<0.001), although there was a wide range between individual patients. Gene expression was higher in men versus women: ERCC1: 2.51 versus 2.22 (p = 0.005); RRM1: 1.41 versus 1.24 (p = 0.004); TS: 3.23 versus 2.83 (p < 0.001). However, SCCA was more frequent in men versus women (30%/19%; p < 0.001). When AC and SCCA were assessed separately, the statistical significance between gene expression and sex was lost (in SCCA: ERCC1, p = 0.14; RRM1, p = 0.26; TS, p = 0.11).

Conclusions: This analysis represents the largest data set for gene expression of these biomarkers reported so far. Significant histology-related associations for ERCC1, RRM1, and TS are seen. However, marked heterogeneity exists in individual patient tumor expression levels. Randomized phase III trials assessing the predictive value of these chemotherapy-related biomarkers are warranted.

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e318287c3c5DOI Listing
May 2013
25 Reads

Publication Analysis

Top Keywords

lung cancer
12
non-small-cell lung
12
cancer patients
4
reported differences
4
factor reported
4
individual non-small-cell
4
differences chemotherapy
4
specimens 2540
4
outcomes squamous
4
chemotherapy outcomes
4
2540 individual
4
patients analyzed
4
contributing factor
4
1457 categorized
4
reductase rrm1
4
ercc1 ribonucleotide
4
categorized sccaresults
4
rrm1 thymidylate
4
thymidylate synthase
4
analyzed biomarkers
4

Similar Publications